Inter-ministerial council launches...Will medical abortion pills be approved?

Inter-ministerial council chaired by the Prime Minister's Office...MOHW is reviewing the "Clinical guidelines·National health insurance reimbursement"

Attention to changes in marketing authorization review by the MFDS...medical community prioritizes "standard guidelines ·post-marketing monitoring"

The domestic introduction of medical abortion pills, long stalled due to legislative gaps and inter-ministerial differences, is being processed.

​Following presidential directives calling for its introduction, inter-agency consultations led by the Prime Minister’s Office have been initiated, while concrete government action plans are taking shape, such as the Ministry of Health and Welfare (MOHW) initiating support for academic societies to establish clinical practice guidelines and reviewing National Health Insurance (NHI) reimbursement.

​President Lee Jae Myung's remarks during a Cabinet meeting on July 14 called for speedy entry. President Lee stated, "Leaving women to purchase abortion medications through overseas direct purchases because they are not permitted domestically is irresponsible of the government," adding, "Rather than concentrating on legislating gestational age limits, we must devise pragmatic measures, such as leaving decisions to physician discretion".

​Following the presidential directive, government action swiftly transitioned into an operational phase. An inter-ministerial council chaired by the Prime Minister's Office, involving the Ministry of Justice, the MOHW, the Ministry of Gender Equality and Family, and the Ministry of Government Legislation, is currently convened and in close discussions regarding medication administration frameworks and public communication strategies.

​In particular, the MOHW is specifying follow-up actions as one of the primary competent ministries. After holding a closed-door briefing session for working-level discussions on introducing the medication, the ministry is preparing institutional frameworks based on its formal introduction.

​During a National Assembly briefing on the 19th, Minister of Health and Welfare Jung Eun Kyeong said the ministry will support deliberations so professional medical societies can autonomously establish clinical practice guidelines for safe use after drug approval.

​Furthermore, drawing upon the current National Health Insurance reimbursement system for surgical abortion procedures under the Mother and Child Health Act, the ministry has commenced preliminary reviews regarding eligible patient populations and coverage criteria to be applied upon medication rollout. This is interpreted as the government’s commitment not merely to grant regulatory approval, but to integrate the therapy into the institutional healthcare system formally.

​As inter-agency preparations advance, attention is also turning to the regulatory agency, the Ministry of Food and Drug Safety (MFDS). Hyundai Pharm's "Mifegymiso" (a mifepristone/misoprostol combination agent), which submitted a marketing authorization application as South Korea’s first oral medication abortion product, has remained in 'under review' status for two years since its late 2024 re-application.  

​The MFDS had previously maintained the principled stance that statutory standards must precede the establishment of approved indications and Risk Management Plans (RMP). However, as prior legal consultations for the MFDS and MOHW, as well as research by the Korea Legislation Research Institute, had concluded that "product approval is permissible irrespective of statutory revisions provided the drug satisfies standards under the Pharmaceutical Affairs Act," MFDS Minister Oh Yu-Kyoung adopted an open, proactive stance at the parliamentary briefing, stating, "We are conducting a comprehensive review by gathering diverse opinions and deliberating within the consultative body led by the Prime Minister."

​The government's push to expedite introduction is driven by the assessment that safety blind spots caused by illicit distribution have grown severe. Identification of illegal online sales and brokerage of unapproved medication abortion products totaled 3,189 cases over the past five years, with 449 cases already caught between January and July 2026 alone, as threats to women's health rights caused by clandestine overseas direct purchasing persist.

​However, overcoming pushback from the medical community remains a prerequisite for introduction and seamless real-world adoption. Obstetrics and gynecology medical associations point out that authorizing prescriptions without statutory frameworks and definitive criteria could escalate legal disputes and adverse event risks. Specialists are calling for concrete safety mechanisms, including: ▲​gestational age confirmation system via ultrasonographic diagnosis ▲establishment of standardized national clinical practice guidelines ▲implementation of a post-administration follow-up tracking system in preparation for emergencies.

​With inter-ministerial coordination led by the Prime Minister's Office, alongside MOHW's preparation of clinical guidelines and NHI reimbursement coverage, as well as the MFDS's regulatory review, the introduction of medical abortion pills has entered the public eye. Attention is focused on whether a pragmatic executive-level alternative will be finalized alongside legislative reform debates in the National Assembly.